CYFIP2 CRISPR/Cas9 KO Plasmid (m): sc-429445
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYFIP2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CYFIP2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CYFIP2 Antibody (6-YD16): sc-134308
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYFIP2 CRISPR/Cas9 KO Plasmid (m) | sc-429445 | 20 µg | $397.00 |
Overview
Cyfip2 encodes CYFIP2, a cytoplasmic effector that couples Rac1 signaling to actin cytoskeleton remodeling and translational control through interactions with the WAVE regulatory complex and FMRP-associated ribonucleoprotein assemblies. In neurons, CYFIP2 contributes to growth cone dynamics, dendritic spine maturation, and synaptic plasticity by coordinating Arp2/3-driven actin polymerization with activity-dependent protein synthesis. These processes position CYFIP2 at the interface of cytoskeletal organization and RNA metabolism, linking it to pathways underlying neuronal connectivity and excitatory synapse function. Altered CYFIP2 activity has been associated with neurodevelopmental phenotypes and seizure-related susceptibility in genetic and functional studies, supporting its relevance for mechanistic modeling in mouse systems.
CYFIP2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cyfip2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cyfip2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cyfip2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CYFIP2 protein expression.
This CRISPR knockout system enables efficient generation of Cyfip2-deficient cell models for investigation of CYFIP2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Cyfip2 exon(s) critical for CYFIP2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Cyfip2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CYFIP2 CRISPR/Cas9 KO Plasmid (m) and CYFIP2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cyfip2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CYFIP2 HDR Plasmid (m) and CYFIP2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cyfip2 homology arms to support homology-directed repair at defined Cyfip2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.